Menveo
Sponsors
Public Health England, GlaxoSmithKline, EuBiologics Co.,Ltd, University of Oxford, EyeGene Inc.
Conditions
DiarrhoeaInfection, MeningococcalMalaria,FalciparumMeningococcal InfectionsMeningococcal MeningitisNervous System DiseasesShigella Sonnei Infection
Phase 1
Phase 2
Comparison of Two Meningococcal ACWY Conjugate Vaccines
CompletedNCT01192997
Start: 2012-06-30End: 2014-03-31Updated: 2020-10-01
A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults
CompletedNCT02676895
Start: 2016-08-08End: 2017-03-10Updated: 2019-02-18
CVIA 106 - Phase 2/3 study of the EuBiologics pentavalent meningococcal ACWYX conjugate vaccine compared to MENVEO® or Nimenrix ® in healthy children through adults
RecruitingPACTR202407771418605
Start: 2024-08-20Target: 4236Updated: 2026-01-27
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
Active, not recruitingNCT07183371
Start: 2025-12-15End: 2026-12-01Target: 360Updated: 2026-03-11
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
RecruitingNCT07204457
Start: 2025-10-15End: 2027-06-30Target: 1123Updated: 2025-12-01
Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children
Not yet recruitingNCT07320716
Start: 2026-01-02End: 2028-10-31Target: 528Updated: 2026-01-06